The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors (Q36964700)

17 August 2017

1 reference

title

The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors (English)

1 reference

17 August 2017

Omar Khan

1

1 reference

PubMed ID

17922622

17 August 2017

Mark R Middleton

series ordinal

2

1 reference

PubMed ID

17922622

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

1 reference

17 August 2017

16

1 reference

17 August 2017

10

1 reference

17 August 2017

1573-1584

1 reference

Affinity purification and characterization of human O6-alkylguanine-DNA alkyltransferase complexed with BCNU-treated, synthetic oligonucleotide

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Temozolomide for recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Systemic chemotherapy in the treatment of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Alkylation damage in DNA and RNA--repair mechanisms and medical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Clinical relevance of MGMT in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Response of repair-competent and repair-deficient Escherichia coli to three O6-substituted guanines and involvement of methyl-directed mismatch repair in the processing of O6-methylguanine residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

In vivo formation and repair of O6-methylguanine in human leukocyte DNA after intravenous exposure to dacarbazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Mismatch repair and DNA damage signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Mechanisms and consequences of methylating agent-induced SCEs and chromosomal aberrations: a long road traveled and still a far way to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Variability and regulation of O6-alkylguanine-DNA alkyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Effect of 5-azacytidine on expression of the human DNA repair enzyme O6-methylguanine-DNA methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Association between growth stimulation by phenobarbital and expression of cytochromes P450 1A1, 1A2, 2B1/2 and 3A1 in hepatic hyperplastic nodules in male F344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

The delivery of BCNU to brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Monosaccharide-linked inhibitors of O(6)-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Hematopoietic stem cell transduction and amplification in large animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

The multifaceted mismatch-repair system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

DNA methylation, chromatin inheritance, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1573

10.1517/13543784.16.10.1573

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17922622